Furthermore, the current national and international guidelines for T2D care recommend the use of GLP-1 RA as a first-line or second-line (after metformin) therapy, taking in consideration the additional benefits on body weight and cardiorenal risk (2, 3). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.